A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.


Pharmaceutical Technology
pp. s28-s31

Acknowlegments

This work was supported in part by the National Cancer Institute of the National Institutes of Health under award number R43CA126070 and R43CA128752. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Brian Schram, PhD, is a senior scientist, Matt Howard is a research scientist, Marjorie Curet is a senior scientist, and Rachel Kravitz, PhD, is director of research, all at Neoclone, Madison WI. Voula Kodoyianni, PhD*, is a product manager at Thermo Fisher Scientific, Madison, WI. *

References

1. Datamonitor Pipeline Insight, "Biologic Targeted Cancer Therapies, Next Generation Jostles for Market Position," DMHC2573. (2009).

2. G. Kohler and C. Milstein, Nature 256, 495–497 (1975).

3. R. Fagnani, Immunol Ser 61, 3–22 (1994).

4. R. Fagnani, S. Halpern, and M. Hagan, Nucl. Med. Commun. 16, 362–369 (1995).

5. M. B. Khazaeli, R. M. Conry, and A. F. LoBuglio, J. Immunother. Emphasis Tumor Immunol. 15, 42–52 (1994).

6. P. Mitchell, Nat. Biotechnol. 23, 906 (2005).

7. M. C. Via, "Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment," (Insight Pharma Reports, 2010).

8. N. R. Gonzales et al., Mol. Immunol. 41, 863–872 (2004).

9. S. V. Kashmiri et al., Methods 36, 25–34 (2005).

10. J. Osbourn, M. Groves, and T. Vaughan, Methods 36, 61–68 (2005).

11. D. M. Fishwild et al., Nat. Biotechnol. 14, 845–851 (1996).

12. L. L. Green, J. Immunol. Methods 231, 11–23 (1999).

13. L. L. Green et al., Nat. Genet. 7, 13–21 (1994).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here